MLYS

Mineralys TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

30%

Probability

Target price

$52.00

+80.2% vs current

Most likely

Base case

45%

Probability

Target price

$36.00

+24.8% vs current

B-

Bear case

25%

Probability

Target price

$18.00

-37.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Tone is modestly constructive because the company converted the story into an FDA-review timeline with runway through 2028, but the T+3 setup does not show strong external revision confirmation yet. Immediate post-release coverage suggested only a modestly positive market reaction, and no trustworthy checked source established a broad analyst upgrade cycle as of 2026-05-08. With medium coverage and sparse non-company confirmation, this remains a cautious catalyst-monitoring view rather than a high-conviction momentum call.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-01catalystPost-earnings debate shifts to launch-readiness progress versus cost rampHigh impact

Q1 highlighted lower R&D after the pivotal program concluded, but materially higher G&A from professional fees and personnel as the company prepares for launch; near-term sentiment likely depends on whether investors view that spend as disciplined pre-commercial buildout or early overhead creep [#8-K-2026-05-06].

2026-12-22eventFDA review path for lorundrostat now centers on the December 22, 2026 PDUFA dateHigh impact

Mineralys said the FDA accepted the lorundrostat NDA for hypertension in combination with other antihypertensive drugs and assigned a December 22, 2026 PDUFA target date, turning the thesis into a regulatory execution story rather than a near-term data story [#8-K-2026-05-06].

2028-01-01catalystCash runway supports pre-commercial and regulatory work into 2028High impact

The company reported $646.1 million of cash, cash equivalents and investments at March 31, 2026 and said existing capital should fund planned trials, regulatory activity, and operations into 2028, which lowers financing pressure ahead of the FDA decision [#8-K-2026-05-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology